📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals's GHG Emissions Data Preview
In 2024, Hikma Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Hikma Pharmaceuticals has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
aVerified Sources Behind Hikma Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Hikma Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Insights into Hikma Pharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions ofHikma Pharmaceuticals amounted to125,705metric tons of CO2 equivalent.This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Hikma Pharmaceuticalsdecreased by 1.3%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
Hikma Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Hikma Pharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Hikma Pharmaceuticals were 38,468 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Has Hikma Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2020, Hikma Pharmaceuticals's Scope 1 emissions have decreased by 18.8%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year(2023), Hikma Pharmaceuticals's Scope 1 emissions decreased by 12.23%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
What are Hikma Pharmaceuticals's Scope 2 emissions?
In 2024, Hikma Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 81,804 tCOâ‚‚e using the market-based method and 87,237 tCOâ‚‚e using the location-based method.a
Has Hikma Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2020, Hikma Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Location-Based)have remained relatively stable, indicating that Hikma Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
Compared to the previous year(2023), Hikma Pharmaceuticals's Scope 2 emissions(Location-Based) have remained relatively stable, indicating that Hikma Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
What methodology does Hikma Pharmaceuticals use for Scope 2 reporting?
In 2024, Hikma Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.a
Hikma Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into Hikma Pharmaceuticals's Value Chain Emissions
In 2024, Hikma Pharmaceuticals reported 860,710 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Hikma Pharmaceuticals includes a breakdown across 9of the 15 Scope 3 categories defined by the GHG Protocol,up from 7 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
Hikma Pharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Hikma Pharmaceuticals's Scope 3 emissions?
In 2024, Hikma Pharmaceuticals reported total Scope 3 emissions of 860,710 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Approximately 94.15%of these emissions originated from upstream activities such as purchased goods and capital goods, while 5.85%came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), Hikma Pharmaceuticals's Scope 3 emissions remained relatively stable, indicating that Hikma Pharmaceuticals's emissions have plateaued with no significant change in its value chain footprint.a
What categories of Scope 3 emissions does Hikma Pharmaceuticals disclose?
In 2024, Hikma Pharmaceuticals reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Hikma Pharmaceuticals's Scope 3 emissions?
In 2024, the largest contributors to Hikma Pharmaceuticals's Scope 3 emissions were:a
- Purchased Goods and Services (Cat. 1): 681,235 tCOâ‚‚e(79.15%)
- Capital Goods (Cat. 2): 46,580 tCOâ‚‚e(5.41%)
- Use of Sold Products (Cat. 11): 42,089 tCOâ‚‚e(4.89%)
Hikma Pharmaceuticals's Scope 3 Emissions by Categories
Insights into Hikma Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Hikma Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 38,468 tCOâ‚‚e and total revenues of USD 2,307 millions. This translates into an emissions intensity of 16.67 tCOâ‚‚e per millions USD.a
Hikma Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers
How does Hikma Pharmaceuticals's GHG emissions intensity compare to its peers?
In 2024, Hikma Pharmaceuticals reported a Scope 1 emissions intensity of 16.67 tCOâ‚‚e per millions USD. Compared to the peer group median of 14.5, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
Where does Hikma Pharmaceuticals rank on GHG emissions intensity within its industry?
In 2024, Hikma Pharmaceuticals ranked 14 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCOâ‚‚e per millions USD).a
Hikma Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
Insights into Hikma Pharmaceuticals's Total Carbon Footprint
In 2024, Hikma Pharmaceuticals reported a total carbon footprint of 986,415 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.29% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Hikma Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 87.26% of the company's total carbon footprint, followed by Scope 2 emissions at 8.84%.a